UPDATE: Cantor Fitzgerald Starts Osmotica (OSMT) at Overweight

September 24, 2021 6:07 AM EDT
Get Alerts OSMT Hot Sheet
Price: $1.94 +3.19%

Rating Summary:
    6 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 14 | Down: 19 | New: 48
Trade Now! 
Join SI Premium – FREE
(Updated - September 24, 2021 6:09 AM EDT)

Cantor Fitzgerald analyst Louise Chen initiates coverage on Osmotica (NASDAQ: OSMT) with a Overweight rating and a price target of $6.00.

The analyst comments "We are initiating coverage of Osmotica Pharmaceuticals (OSMT) with an Overweight rating and a 12-month price target of $6. OSMT’s commercial opportunities are underappreciated, in our view. Therefore, we expect upwards earnings estimate revisions by the Street to drive the stock higher. We anticipate that these revisions could come from potential upcoming catalysts, which include: 1) roll out of Buy and Bill program to eye care centers in geographies that permit it in 4Q21, 2) build out of an aesthetic team and preparation to launch into aesthetic space by the end of 2021, and 3) commencement of value share program in New York and Texas in 1Q22."

For an analyst ratings summary and ratings history on Osmotica click here. For more ratings news on Osmotica click here.

Shares of Osmotica closed at $2.93 yesterday.

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage

Related Entities

Cantor Fitzgerald, Earnings, Louise Chen